THE PROGNOSTIC VALUE OF PRETREATMENT EXPRESSION OF ANDROGEN RECEPTOR AND BCL-2 IN HORMONALLY TREATED PROSTATE CANCER PATIENTS

Abstract

The expression of bcl-2 and androgen receptor in pretreatment prostate cancer specimens is not related to the prognosis of hormonally treated prostate cancer. Bcl-2 expression is not increased in endocrine therapy resistant prostate cancer. Surprisingly, a combined bcl-2/androgen receptor score acts as an independent prognosticator for clinical progression.